PF-Atlas › Clinical Trials › NCT02265679

Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis Patients

BIIL 284 BS, low dose, pediatric patients · Phase 1

Registry ID
NCT02265679
Phase
Phase 1
Status
Completed
Drug / intervention
BIIL 284 BS, low dose, pediatric patients
Sponsor
Boehringer Ingelheim
Start
2001-10
Enrollment
45

About this trial

Safety, tolerability and pharmacokinetics following single doses

View NCT02265679 on ClinicalTrials.gov →

Explore related

All BIIL 284 BS, low dose, pediatric patients trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT02265679 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.